(2-pyridyldithio)-PEG4 acid is a cleavable ADC linker with pyridyldithiol for thiol-reactive conjugation and PEG spacer for solubility. Widely used in targeted antibody-drug conjugate design to improve payload stability and release.
Structure of 581065-93-2
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
(2-pyridyldithio)-PEG4 acid, a versatile linker molecule with widespread utility in biochemical and biotechnological fields, serves as a cornerstone of innovation in various applications. Here are four key applications eloquently presented with a high degree of perplexity and burstiness:
Bioconjugation: The strategic utilization of (2-pyridyldithio)-PEG4 acid in bioconjugation endeavors enables the seamless coupling of biomolecules, such as proteins, antibodies, and peptides, to a diverse array of surfaces or other biomolecules. Acting as a sophisticated spacer, it deftly mitigates steric hindrances while fortifying the stability and functionality of the resultant conjugates. This pivotal role is instrumental in propelling the evolution of state-of-the-art biosensors, diagnostic tools, and therapeutic agents, reshaping the very fabric of biotechnological advancements.
Drug Delivery Systems: By integrating (2-pyridyldithio)-PEG4 acid into the realm of drug delivery systems, a realm of revolutionary precision unfolds before us. This strategic integration enables the precise attachment of therapeutic agents to carrier molecules like nanoparticles or liposomes, ushering in an era of enhanced targeting and controlled release of drugs to specific tissues or cells. This amplification of treatment efficacy, while concurrently minimizing side effects, exemplifies the transformational potential of such systems, catapulting personalized medicine and targeted cancer therapies to unprecedented levels of precision and efficacy.
Protein PEGylation: Nestled within the intricate domain of protein PEGylation, (2-pyridyldithio)-PEG4 acid assumes a pivotal role in the covalent attachment of polyethylene glycol (PEG) chains to proteins. Through the enhancement of solubility, stability, and circulating half-life of therapeutic proteins, PEGylation profoundly augments their pharmacokinetic properties, heralding a new era in the production of biopharmaceuticals like interferons and growth hormones. This streamlined approach to the development of cutting-edge protein-based therapies underscores the transformative power of (2-pyridyldithio)-PEG4 acid in reshaping the therapeutic landscape.
Surface Modification: The adaptability of (2-pyridyldithio)-PEG4 acid finds vibrant expression in surface modification applications, where it serves as a linchpin for altering the surfaces of diverse materials such as gold nanoparticles, glass, and polymers. This transformative modification enhances biocompatibility and diminishes non-specific binding, assuming a pivotal role in the design of biocompatible medical devices, tissue engineering scaffolds, and biosensor platforms. By facilitating the creation of inert surfaces, this application undergirds the development of reliable and effective biomedical technologies, propelling relentless innovation in this dynamic field.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00891 | (2-pyridyldithio)-PEG1-hydrazine | 111625-28-6 | |
BADC-01522 | (2-Pyridyldithio)-PEG6 acid |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.